DELopen is a platform connecting industry and academic research institutions to realize effective sharing of scientific research information and protection of intellectual property. Through this platform, researchers and institutions engaged in the development of new drugs with DEL technology can more quickly conduct early new drug development and expedite the development of results to commercialization as soon as possible.

Institutions interested in using the DELopen compound library for target screening can access libraries and perform affinity screening against billions of compounds with no cost or commitment. The structure information of the compound library and target information are confidential to both parties. After screening by the researcher, the experimental results are returned to the owner of the compound library for subsequent PCR / Sequencing. Once positive results are found, all parties can communicate with each other for further collaboration.

The board will set the direction and guide the development of DELopen in its vision to advance the adoption of DNA encoded library technology in new drug discovery.